NR 607 Midterm Exam Prep Document | 2026/2027 Edition |
200 Verified Questions - 150 Questions with Answers
NR 607 Midterm Exam 2026-150 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified
Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation resource for NR 607 (Advanced Pharmacology) at Chamberlain
University provides 200 verified questions that mirror the actual midterm exam. Each question is
accompanied by correct answers and rationales, ensuring a thorough review of key pharmacological
concepts. The content is organized by body systems and drug classes, reflecting the course syllabus.
Updated for the 2026/2027 academic year, this document is an essential tool for nursing students
aiming to excel in their midterm examination.
Key Features:
Pharmacokinetics and Pharmacodynamics
Autonomic Nervous System Drugs
Cardiovascular Pharmacology
Respiratory Pharmacology
Endocrine Pharmacology
Neurological and Psychiatric Pharmacology
Analgesics and Anti-inflammatory Agents
Antimicrobial Therapy
Chemotherapy and Immunopharmacology
Gastrointestinal Pharmacology
Dermatological and Ophthalmic Agents
Special Populations (Pediatric, Geriatric, Pregnancy)
Drug Interactions and Adverse Reactions
Prescribing and Monitoring Guidelines
Patient Education and Adherence
Evidence-Based Pharmacotherapy
Legal and Ethical Considerations in Prescribing
Case-Based Clinical Scenarios
Updates for 2026:
- Revised to align with the latest 2026/2027 Chamberlain University NR 607 curriculum
- Incorporated new FDA-approved medications and updated prescribing guidelines
- Enhanced rationales with current evidence-based practice references
- Added expanded coverage of COVID-19 related pharmacotherapy and vaccines
- Updated questions to reflect recent changes in drug safety warnings and black box alerts
Abstract:
This midterm exam preparation document for NR 607 Advanced Pharmacology at Chamberlain University offers a
rigorous review of pharmacological principles and clinical applications. It encompasses 200 verified questions
that span the entire course curriculum, from foundational pharmacokinetics to complex therapeutic regimens for
chronic diseases. Each question is meticulously crafted to assess critical thinking and clinical reasoning, with
detailed rationales that reinforce learning. The content is organized systematically, allowing students to focus on
specific body systems or drug classes. Updated to reflect the 2026/2027 academic year, this resource integrates the
latest evidence-based guidelines and drug approvals. It is an indispensable tool for nursing students seeking to
Page 1
,achieve a high score on the midterm exam and to enhance their pharmacological competence in clinical practice.
Keywords:
NR 607, Advanced Pharmacology, Midterm Exam Prep, Chamberlain University, Verified Questions, Nursing
Pharmacology, Drug Therapy, Clinical Pharmacology
Answer Format:
Each question is presented in a multiple-choice format with four options. The correct answer is clearly indicated,
followed by a comprehensive rationale explaining why it is correct and why the other options are incorrect.
Distractor analysis is provided to clarify common misconceptions, and clinical pearls are included to enhance
application.
Compliance Checklist:
All questions align with the NR 607 course objectives and Chamberlain University's curriculum
Answers are verified by subject matter experts and cross-referenced with current pharmacological references
Rationales are evidence-based and cite reputable sources such as FDA guidelines and peer-reviewed literature
Content is updated for the 2026/2027 academic year, including new drug approvals and safety alerts
The document is formatted for easy navigation and self-assessment, with clear section headers and question
numbering
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of Pharmacology 1-20 Pharmacokinetics, Pharmacodynamics, Drug 10%
Interactions, Adverse Drug Reactions
Autonomic Nervous System 21-40 Cholinergic Agonists/Antagonists, 10%
Drugs Adrenergic Agonists/Antagonists,
Sympathomimetics, Parasympatholytics
Cardiovascular Pharmacology 41-70 Antihypertensives, Antiarrhythmics, 15%
Antianginals, Heart Failure Medications,
Anticoagulants/Antiplatelets
Respiratory Pharmacology 71-85 Bronchodilators, Corticosteroids, 8%
Antihistamines, Decongestants,
Expectorants/Antitussives
Endocrine Pharmacology 86-110 Insulin and Antidiabetics, Thyroid 12%
Medications, Corticosteroids, Sex
Hormones, Osteoporosis Drugs
Neurological and Psychiatric 111-135 Antiepileptics, Antiparkinson Agents, 12%
Pharmacology Antidepressants, Antipsychotics,
Anxiolytics, Stimulants
Analgesics and 136-150 Opioids, NSAIDs, Acetaminophen, Muscle 8%
Anti-inflammatory Agents Relaxants, Gout Medications
Antimicrobial Therapy 151-170 Penicillins, Cephalosporins, Macrolides, 10%
Tetracyclines, Fluoroquinolones, Antivirals,
Antifungals
Chemotherapy and 171-180 Cytotoxic Agents, Targeted Therapy, 5%
Immunopharmacology Immunosuppressants, Monoclonal
Antibodies
Page 2
,Gastrointestinal Pharmacology 181-190 Antacids, Proton Pump Inhibitors, H2 5%
Blockers, Antiemetics, Laxatives,
Antidiarrheals
Special Populations and 191-200 Pediatric and Geriatric Considerations, 5%
Miscellaneous Pregnancy and Lactation, Dermatological
Agents, Ophthalmic Agents
Page 3
, Q1. A patient on long-term haloperidol develops akathisia, which persists despite dose
reduction. Which adjunctive agent is most evidence-based for this specific adverse
effect?
A. Benztropine
B. Propranolol
C. Diphenhydramine
D. Lorazepam
Correct Answer: B. Propranolol
Rationale: Akathisia is often resistant to anticholinergics; beta-blockers like propranolol
are the most evidence-based treatment. Benztropine and diphenhydramine are more
effective for dystonia and parkinsonism. Lorazepam provides only transient relief.
Why Wrong:
A - Benztropine is effective for EPS but not typically for akathisia.
C - Diphenhydramine is an anticholinergic with limited efficacy for akathisia.
D - Lorazepam may reduce anxiety but not the core akathisia symptoms.
Reference: Stahl, S.M. (2021). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 5
Q2. Which laboratory finding is most critical to monitor in a patient starting
clozapine, given the risk of a specific fatal adverse effect?
A. Absolute neutrophil count (ANC)
B. Serum creatinine
C. Liver enzymes (ALT/AST)
D. Fasting blood glucose
Correct Answer: A. Absolute neutrophil count (ANC)
Rationale: Clozapine can cause agranulocytosis, a potentially fatal drop in ANC,
requiring mandatory monitoring. Renal and hepatic function are less critical.
Hyperglycemia is a metabolic concern but not the most immediately life-threatening.
Why Wrong:
B - Renal function is not routinely monitored for clozapine.
C - Hepatic monitoring is not the primary safety concern.
D - Glucose is important but not the most critical acute risk.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 15
Q3. A patient with bipolar I disorder is stabilized on lithium. Which drug interaction
can significantly increase lithium levels and risk of toxicity?
A. Ibuprofen (NSAID)
B. Acetaminophen
C. Aspirin (low dose)
Page 4
200 Verified Questions - 150 Questions with Answers
NR 607 Midterm Exam 2026-150 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified
Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation resource for NR 607 (Advanced Pharmacology) at Chamberlain
University provides 200 verified questions that mirror the actual midterm exam. Each question is
accompanied by correct answers and rationales, ensuring a thorough review of key pharmacological
concepts. The content is organized by body systems and drug classes, reflecting the course syllabus.
Updated for the 2026/2027 academic year, this document is an essential tool for nursing students
aiming to excel in their midterm examination.
Key Features:
Pharmacokinetics and Pharmacodynamics
Autonomic Nervous System Drugs
Cardiovascular Pharmacology
Respiratory Pharmacology
Endocrine Pharmacology
Neurological and Psychiatric Pharmacology
Analgesics and Anti-inflammatory Agents
Antimicrobial Therapy
Chemotherapy and Immunopharmacology
Gastrointestinal Pharmacology
Dermatological and Ophthalmic Agents
Special Populations (Pediatric, Geriatric, Pregnancy)
Drug Interactions and Adverse Reactions
Prescribing and Monitoring Guidelines
Patient Education and Adherence
Evidence-Based Pharmacotherapy
Legal and Ethical Considerations in Prescribing
Case-Based Clinical Scenarios
Updates for 2026:
- Revised to align with the latest 2026/2027 Chamberlain University NR 607 curriculum
- Incorporated new FDA-approved medications and updated prescribing guidelines
- Enhanced rationales with current evidence-based practice references
- Added expanded coverage of COVID-19 related pharmacotherapy and vaccines
- Updated questions to reflect recent changes in drug safety warnings and black box alerts
Abstract:
This midterm exam preparation document for NR 607 Advanced Pharmacology at Chamberlain University offers a
rigorous review of pharmacological principles and clinical applications. It encompasses 200 verified questions
that span the entire course curriculum, from foundational pharmacokinetics to complex therapeutic regimens for
chronic diseases. Each question is meticulously crafted to assess critical thinking and clinical reasoning, with
detailed rationales that reinforce learning. The content is organized systematically, allowing students to focus on
specific body systems or drug classes. Updated to reflect the 2026/2027 academic year, this resource integrates the
latest evidence-based guidelines and drug approvals. It is an indispensable tool for nursing students seeking to
Page 1
,achieve a high score on the midterm exam and to enhance their pharmacological competence in clinical practice.
Keywords:
NR 607, Advanced Pharmacology, Midterm Exam Prep, Chamberlain University, Verified Questions, Nursing
Pharmacology, Drug Therapy, Clinical Pharmacology
Answer Format:
Each question is presented in a multiple-choice format with four options. The correct answer is clearly indicated,
followed by a comprehensive rationale explaining why it is correct and why the other options are incorrect.
Distractor analysis is provided to clarify common misconceptions, and clinical pearls are included to enhance
application.
Compliance Checklist:
All questions align with the NR 607 course objectives and Chamberlain University's curriculum
Answers are verified by subject matter experts and cross-referenced with current pharmacological references
Rationales are evidence-based and cite reputable sources such as FDA guidelines and peer-reviewed literature
Content is updated for the 2026/2027 academic year, including new drug approvals and safety alerts
The document is formatted for easy navigation and self-assessment, with clear section headers and question
numbering
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of Pharmacology 1-20 Pharmacokinetics, Pharmacodynamics, Drug 10%
Interactions, Adverse Drug Reactions
Autonomic Nervous System 21-40 Cholinergic Agonists/Antagonists, 10%
Drugs Adrenergic Agonists/Antagonists,
Sympathomimetics, Parasympatholytics
Cardiovascular Pharmacology 41-70 Antihypertensives, Antiarrhythmics, 15%
Antianginals, Heart Failure Medications,
Anticoagulants/Antiplatelets
Respiratory Pharmacology 71-85 Bronchodilators, Corticosteroids, 8%
Antihistamines, Decongestants,
Expectorants/Antitussives
Endocrine Pharmacology 86-110 Insulin and Antidiabetics, Thyroid 12%
Medications, Corticosteroids, Sex
Hormones, Osteoporosis Drugs
Neurological and Psychiatric 111-135 Antiepileptics, Antiparkinson Agents, 12%
Pharmacology Antidepressants, Antipsychotics,
Anxiolytics, Stimulants
Analgesics and 136-150 Opioids, NSAIDs, Acetaminophen, Muscle 8%
Anti-inflammatory Agents Relaxants, Gout Medications
Antimicrobial Therapy 151-170 Penicillins, Cephalosporins, Macrolides, 10%
Tetracyclines, Fluoroquinolones, Antivirals,
Antifungals
Chemotherapy and 171-180 Cytotoxic Agents, Targeted Therapy, 5%
Immunopharmacology Immunosuppressants, Monoclonal
Antibodies
Page 2
,Gastrointestinal Pharmacology 181-190 Antacids, Proton Pump Inhibitors, H2 5%
Blockers, Antiemetics, Laxatives,
Antidiarrheals
Special Populations and 191-200 Pediatric and Geriatric Considerations, 5%
Miscellaneous Pregnancy and Lactation, Dermatological
Agents, Ophthalmic Agents
Page 3
, Q1. A patient on long-term haloperidol develops akathisia, which persists despite dose
reduction. Which adjunctive agent is most evidence-based for this specific adverse
effect?
A. Benztropine
B. Propranolol
C. Diphenhydramine
D. Lorazepam
Correct Answer: B. Propranolol
Rationale: Akathisia is often resistant to anticholinergics; beta-blockers like propranolol
are the most evidence-based treatment. Benztropine and diphenhydramine are more
effective for dystonia and parkinsonism. Lorazepam provides only transient relief.
Why Wrong:
A - Benztropine is effective for EPS but not typically for akathisia.
C - Diphenhydramine is an anticholinergic with limited efficacy for akathisia.
D - Lorazepam may reduce anxiety but not the core akathisia symptoms.
Reference: Stahl, S.M. (2021). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 5
Q2. Which laboratory finding is most critical to monitor in a patient starting
clozapine, given the risk of a specific fatal adverse effect?
A. Absolute neutrophil count (ANC)
B. Serum creatinine
C. Liver enzymes (ALT/AST)
D. Fasting blood glucose
Correct Answer: A. Absolute neutrophil count (ANC)
Rationale: Clozapine can cause agranulocytosis, a potentially fatal drop in ANC,
requiring mandatory monitoring. Renal and hepatic function are less critical.
Hyperglycemia is a metabolic concern but not the most immediately life-threatening.
Why Wrong:
B - Renal function is not routinely monitored for clozapine.
C - Hepatic monitoring is not the primary safety concern.
D - Glucose is important but not the most critical acute risk.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 15
Q3. A patient with bipolar I disorder is stabilized on lithium. Which drug interaction
can significantly increase lithium levels and risk of toxicity?
A. Ibuprofen (NSAID)
B. Acetaminophen
C. Aspirin (low dose)
Page 4
